A year of red lumps on her face
A 55-year-old woman had lived with red, raised patches on the right side of her face for more than a year. Some bumps were small. Others were the size of a coin.
She had tried four different treatments at another hospital. None worked.
She was running out of options.
Her diagnosis was Rosai-Dorfman disease — a rare condition where immune cells called histiocytes pile up in the skin and other tissues.
Most patients have it in their lymph nodes. Only a small number have it show up on the skin.
When it hits the skin, it can be stubborn. The face form is especially hard because every flare is visible to the world.
The old playbook fell short
Doctors first reached for the usual toolbox. Thalidomide. Methotrexate. Hydroxychloroquine. Steroid shots.
These drugs calm the immune system in different ways. For many rare skin conditions, at least one of them works.
For her, none did.
A fresh combination
That's when doctors tried something different.
First, they added fire needling — a traditional Chinese technique where a thin metal needle is briefly heated and inserted into skin lesions. Think of it like a tiny controlled burn that nudges the body to reset its response.
After two weeks, her skin looked a little better.
Switching to a targeted pill
Then doctors swapped in tofacitinib — a pill used for rheumatoid arthritis and some skin diseases. It blocks a signal pathway called JAK, which helps drive inflammation.
Imagine inflammation as a group chat where cells send each other angry messages. Tofacitinib mutes part of that chat.
Within weeks, her nodules began to flatten and fade.
How the combination likely worked
Fire needling may have weakened the lesions and stirred up local healing. Tofacitinib then kept the immune misfire from starting up again.
It's a pairing of old and new — an ancient technique and a modern targeted drug.
This is the first time either treatment has been used this way for this disease.
What doctors tracked
The team watched her for four months. They checked for side effects. They measured how much the skin flattened and faded.
Her skin kept improving. No worrying side effects showed up.
She also avoided the heavier drugs that had failed her before.
Why this case stands out
Rosai-Dorfman disease is rare. Cutaneous-only cases are rarer. And cases that resist standard treatment are rarer still.
For patients stuck at a dead end, a successful new approach — even in one person — can open doors.
JAK inhibitors like tofacitinib are changing how doctors treat many tough immune-driven skin diseases. They offer a more precise way to quiet inflammation.
Fire needling is harder to study with modern tools, but it has been used for centuries for stubborn skin problems. Combining it with a targeted drug reflects a growing trend — blending evidence-based medicine with older practices when patients have run out of options.
If you have Rosai-Dorfman disease or a similar stubborn skin condition, this report does not mean you should run to the nearest JAK inhibitor.
These drugs carry real risks, including infections and blood clot concerns. They need close monitoring.
What this case does offer is hope — and a conversation starter with your dermatologist or rheumatologist if standard treatments are failing.
One patient is one patient. A case report cannot prove that a treatment works for everyone.
We also don't know how much of her improvement came from the needling, the pill, or simply time. And four months is a short follow-up.
Longer studies with more patients are needed.
Researchers will want to test JAK inhibitors in larger groups of people with cutaneous Rosai-Dorfman disease. Registries — where doctors pool rare cases from many hospitals — will help build real evidence.
For now, this single story offers a clue. Sometimes, the answer to a stubborn problem comes from combining two very different traditions.